PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN THE BIOLOGIC ERA: IMPLICATIONS FOR PRACTICE

Supplement 2 to Volume 78
November 2011
www.ccjm.org/content/78/Suppl_2

Supplement Editor
LEONARD CALABRESE, DO
Cleveland Clinic

Contents

Introduction ................................................................. S2
Leonard Calabrese, DO

History and current concepts in the pathogenesis of PML .................... S3
Eugene O. Major, PhD

The clinical features of PML ........................................... S8
Joseph R. Berger, MD

Pharmacovigilance and PML in the oncology setting ......................... S13
Charles L. Bennett, MD, PhD, MPP

Multiple sclerosis, natalizumab, and PML: Helping patients decide ......... S18
Richard A. Rudick, MD

HIV-associated PML: Changing epidemiology and clinical approach ....... S24
David M. Simpson, MD, FRCP, FAAN

PML and rheumatology: The contribution of disease and drugs .......... S28
Eamonn S. Molloy, MD, MS, MRCPI

Advances in the management of PML: Focus on natalizumab ............... S33
Robert Fox, MD

A rational approach to PML for the clinician ................................ S38
Leonard Calabrese, DO